405O_PR - Cost-effectiveness of pembrolizumab compared to ipilimumab and chemotherapy as a first line treatment for patients with advanced melanoma in Hong Kong

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Melanoma
Topics Anticancer agents
Bioethics, Legal, and Economic Issues
Immunotherapy
Skin Cancers
Presenter Herbert Loong
Citation Annals of Oncology (2016) 27 (suppl_9): ix126-ix129. 10.1093/annonc/mdw589
Authors H.H. Loong1, C.K.H. Wong2, L.K.S. Leung1, M.T.K. Leung3, J. Wang4, K. Stevinson4
  • 1Dept. Of Clinical Oncology, The Chinese University of Hong Kong, 00000 - Hong Kong/HK
  • 2Dept. Of Family Medicine & Primary Care, The University of Hong Kong, 00000 - Hong Kong/HK
  • 3Msd, Hong Kong, MSD, Hong Kong, 00000 - Hong Kong/HK
  • 4Msd Kenilworth, Usa, MSD Kenilworth, USA, 07033 - Kenilworth/US

Abstract

Background

Pembrolizumab (Pembro) has been shown to improve overall survival (OS) and progression free survival (PFS) compared with ipilimumab (Ipi) in patients with Ipi naïve advanced melanoma; however, there are no published data on the cost-effectiveness for Pembro compared with treatments currently used in Hong Kong for advanced melanoma.

Methods

A partitioned-survival model based on data from a recent randomized phase 3 study (KEYNOTE-006) was used to derive cost and time in PFS, OS, and post-progression survival for Pembro and Ipi. Other comparators include dacarbazine (DTIC), temozolomide (TMZ), and the paclitaxel-carboplatin combination (PC). A combination of clinical trial data, literature data, results of meta-analysis, and melanoma registry data was used to derive PFS and OS curves. The base-case time horizon for the model was 10 years with costs and health outcomes discounted at a rate of 5% per year. Individual patient level data on utilities and frequencies of adverse events were obtained from an interim analysis of the KEYNOTE-006 (cut-off date: 3-Mar-15) for Pembro and Ipi. Cost data included drug acquisition, treatment administration, adverse event management, and clinical management of advanced melanoma. Cost information was obtained. The distribution of patient weight from the Hong Kong population was applied to calculate the drug costs. The incremental cost effectiveness ratio (ICER) expressed as cost in US Dollars (USD) per quality-adjusted life years (QALYs) was the main outcome. Sensitivity analyses (probabilistic and one-way) were performed to test the robustness of the results.

Results

The ICER for Pembro as a 1L treatment for advanced melanoma was USD 8,034 compared with Ipi and USD 53,123 compared to DTIC. Results comparing Pembro to TMZ and to PC were similar to that of comparing with DTIC.

Conclusions

Pembro is cost effective relative to Ipi for the treatment of advanced melanoma in Hong Kong. When compared with chemotherapy (DTIC, TMZ and PC), the resulting ICER is also lower than the WHO threshold of three times gross domestic product (GDP) per capita, which, for Hong Kong, is currently at USD 119,274.

Clinical trial indentification


Legal entity responsible for the study

N/A

Funding

MSD

Disclosure

H.H. Loong: Research Funding (not related to submitted abstract) – MSD. M.T.K. Leung: Employee of MSD J. Wang, K. Stevinson: Employee – MSD. All other authors have declared no conflicts of interest.